Related Experiment Video

Updated: Mar 9, 2026

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

11.2K

Analysis to Estimate Genetic Variations in the Idarubicin-Resistant Derivative MOLT-3

Tomoyoshi Komiyama1, Atsushi Ogura2, Takatsugu Hirokawa3

  • 1Department of Clinical Pharmacology, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa 259-1193, Japan. komiyama@tokai-u.jp.

International Journal of Molecular Sciences
|December 28, 2016
PubMed

Insights

Genetic mutations in mitochondrial and nuclear DNA contribute to acute leukemia drug resistance. Researchers identified specific mutations in the ND3 gene and GALNT2 gene in idarubicin-resistant leukemia cells, potentially explaining resistance mechanisms.

Area of Science:

  • Molecular Biology
  • Cancer Genetics
  • Pharmacology

Background:

  • Gene alterations are a known cause of drug resistance in acute leukemia.
  • Understanding these resistance mechanisms is crucial for developing effective chemotherapy strategies.

Purpose of the Study:

  • To investigate the genetic mechanisms of idarubicin resistance in the human acute leukemia cell line MOLT-3/IDR compared to its sensitive counterpart MOLT-3.
  • To identify specific genetic differences, including mutations in mitochondrial and nuclear DNA, associated with drug resistance.

Main Methods:

  • Complete mitochondrial and nuclear DNA analyses were performed on MOLT-3 and MOLT-3/IDR cell lines.
  • Comparative Genomic Hybridization (CGH) array analysis was used to identify genetic alterations.
  • Gene sequencing and real-time PCR were employed to analyze specific gene mutations and expression levels.
  • Protein structure prediction was utilized to assess the impact of identified mutations.

Main Results:

  • A unique mutation (p.Thr61Ile) in the ND3 gene of mitochondrial DNA was identified in MOLT-3/IDR cells.
  • A mutation (G1716K) within the stop codon of the GALNT2 gene was found in MOLT-3/IDR cells, leading to an extended protein.
  • The GALNT2 gene showed a specific expression value (0.35) in the resistant cells.
  • Protein structure prediction indicated a structural change in GALNT2 in MOLT-3/IDR cells.

Conclusions:

  • Specific genetic alterations in both mitochondrial (ND3) and nuclear (GALNT2) DNA distinguish idarubicin-resistant leukemia cells from sensitive ones.
  • The identified GALNT2 mutation, resulting in protein elongation and structural changes, is a potential contributor to idarubicin resistance in acute leukemia.
Keywords:
CGH arrayGALNT2 geneMOLT-3gene polymorphismgenetic variationsidarubicin (IDR)leukemiamitochondrial DNA

More Related Videos

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

25.2K
Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.7K

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
60
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K